NASDAQ
1.84USD
+0.03 (+1.66%)
We have scored 5 news catalysts on Grace Therapeutics, Inc. (GRCE) over the past 12 months. The biggest single-day move next to one of them came Jun 1, 2026, when GRCE closed +4.7%: “Grace Therapeutics: Assessing The Path Forward For GTx-104”. Coverage across the window leans negative (average ticker sentiment −0.58). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
29.9M
P/E
—
EPS
—
Beta
0.41
52W range
1.67-5.18
Day range
1.72–2.01
Open
1.80
Prev close
1.81
Volume
231.1K
Avg volume
178.4K
Dividend
0.00
IPO
2012-02-07
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Grace Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for GRCE: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
